- Home
- TTNP
as 07-26-2024 4:00pm EST
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 5.8M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 6.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.24 - $13.00 | Next Earning Date: | 08-12-2024 |
| Revenue: | $87,000 | Revenue Growth: | -81.25% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Titan Pharmaceuticals Inc. News
TTNP Breaking Stock News: Dive into TTNP Ticker-Specific Updates for Smart Investing
MT Newswires
25 days ago
Top Premarket Gainers
Associated Press Finance
2 months ago
Titan Pharmaceuticals: Q1 Earnings Snapshot
Business Wire
6 months ago
Personalis to Participate at Upcoming Investor Conferences
GlobeNewswire
6 months ago
Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Business Wire
6 months ago
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Business Wire
6 months ago
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Zacks
6 months ago
New Strong Buy Stocks for January 26th
GlobeNewswire
6 months ago
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Compare TTNP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TTNP Titan Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.